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M ammographically detected breast calcifications are analyzed based on morphology and distribution. While the majority of calcifications seen at screening mammography can be dismissed as typically benign, calcifications can be the earliest detectable evidence of breast cancer; 55% of nonpalpable breast cancers have associated calcifications at mammography (1) . Amorphous calcifications are indistinct, appearing so small or hazy even on spot magnification mammograms that more specific morphologic classification cannot be assigned (2) . Historically, management of amorphous calcifications varied from surveillance to biopsy (3) . In 1998, Liberman et al (4) reported that nine of 35 (26%) biopsied amorphous calcifications were malignant. In 2001, in a prospective series of 150 patients in which all amorphous calcifications (other than those scattered in both breasts) were recommended for biopsy, 30 of 150 (20%) patients had malignant lesions (5) . Since that time, such calcifications have generally been assessed as suspicious (Breast Imaging Reporting and Data System [BI-RADS] category 4b), and recommended for biopsy (2, 4, 5) . Subsequently, Burnside et al (6) reported a malignancy rate of four of 30 (13%) for biopsied amorphous calcifications, and Bent et al (7) showed 10 of 51 (20%) lesions were malignant. Importantly, 27 of 30 (90%) cancers reported by Berg et al (5) were ductal carcinoma in situ (DCIS); of the 25 cancers with grading, 15 (60%) were low-nuclear-grade DCIS, and all three invasive malignancies were low grade. To ensure that biopsy of amorphous calcifications remains necessary and to identify possible subgroups of patients in whom surveillance may be a reasonable option, we felt it was important to reevaluate malignancy rates from biopsy of amorphous calcifications using current imaging and histopathologic criteria, to include receptor subtype of the malignancies found, and to determine the upgrade rate to
Materials and Methods
From January 2009 to September 2013, stereotactic vacuumassisted biopsy was attempted in 6727 lesions at the University of Pittsburgh Medical Center (Pittsburgh, Pa). We sought to have analyzable results from approximately 500 biopsies of amorphous calcifications. To achieve this, we reviewed prebiopsy mammograms, including magnification views from 1903 consecutive biopsies (at least 300 from each year), of which 546 (28.7%) were for amorphous calcifications. An alphabetic list of all attempted stereotactic biopsies from a given year was provided to each observer, who then reviewed biopsies sequentially. The primary assessment was performed using 497 lesions after excluding 11 atypical lesions not excised, 25 concurrent lesions biopsied within the same year, and 13 biopsies that were performed of a second group within the same "multiple group" lesion (ie, multiple groups of amorphous calcifications in the same quadrant, detailed in Appendix E1 [online]). Primary findings were verified with analysis of complete data.
Mammograms were retrospectively reviewed by one of six breast-imaging radiologists (W.A.B., H.C.O., S.S.C., S.S., M.A., M.L.Z.) with 0.5-22 years of experience following Abbreviations ADH = atypical ductal hyperplasia, ALH = atypical lobular hyperplasia, BI-RADS = Breast Imaging Reporting and Data System, CI = confidence interval, DCIS = ductal carcinoma in situ, FEA = flat epithelial atypia, IDC = invasive ductal carcinoma, LCIS = lobular carcinoma in situ Summary Amorphous calcifications require tissue biopsy but are infrequently associated with aggressive malignancies, especially when they have solitary grouped distribution. an institutional review board-approved Health Insurance Portability and Accountability Act-compliant protocol. Five radiologists reviewed sequential biopsies from each year respectively (2009-2013, one year for each radiologist). Mammograms of patients considered to have amorphous calcifications were later reviewed by one radiologist (W.A.B.) trained in BI-RADS with 22 years of experience who confirmed calcification morphology and distribution and who was blinded to outcome. In case of disagreement on calcification morphology, the recorded data were based on the experienced radiologist's assessment. Calcification morphology and distribution were recorded, together with associated findings (mass, asymmetry, distortion), largest span of the calcifications, and histopathology results, including results of excision for any malignant or risk lesions (detailed in Appendix E1 [online]). We recorded the distribution as multiple groups when several groups of calcifications were in the same quadrant.
Breast density was recorded using BI-RADS categories (2). Maximum lesion diameter was recorded. Patient demographics, including age, personal history of breast cancer, personal or family history of breast or ovarian cancer, and history of prior atypical breast biopsy, were noted. Histopathology and tumor characteristics from core and excisional biopsy or mastectomy were obtained from the electronic medical record. Location of targeted amorphous calcifications within atypia, malignancy, or both versus adjacent or incidental was recorded as part of usual care.
Histopathologic truth was based on the most severe tissue diagnosis at stereotactic biopsy or excision. If the stereotactic biopsy showed malignancy but excision revealed benign findings, stereotactic results were considered the histopathologic truth, with the assumption that the malignancy was completely removed during core biopsy and all such pathology results showed biopsy site changes at excision. Specimens were interpreted by general pathologists and included detail on the location of calcifications within or adjacent to malignancies or atypia. Malignancy was graded based on the Nottingham classification. For malignancies, intrinsic molecular subtype was inferred from estrogen and progesterone receptor status, human epidermal growth factor 2 status (with reflexive fluorescence in situ hybridization for 2+ at immunohistochemistry), and Ki-67 proliferation rate.
Statistical Analyses
Statistical analyses were performed with software (Proc Freq, SAS, version 9.4; SAS Institute, Cary, NC). Malignancy rates and the corresponding exact 95% confidence intervals (CIs) were estimated by using the Clopper-Pearson approach. Four unusual biopsies in which distribution was classified as other were excluded from further statistical analysis because of small heterogeneous subgroup (detailed in Table 1 footnote). As such, malignancy rates and corresponding exact 95% CIs were estimated based on individual distribution subtypes for a total of 493 lesions (ie, grouped, multiple groups, regional, linear, and segmental). The Fisher exact test was used to compare malignancy rates among all distribution categories and to compare each category to "grouped" lesions (P ,.05 indi- Robustness of the association of calcification distribution with malignancy was verified by considering comparisons adjusted for known potential influential clinical and imaging features. Adjusted relative rates were calculated by using the Mantel-Haenszel approach with the exact test. The multivariable model was built by manual forward selection and verified with automatic backward elimination and by retesting the excluded factors. For subgroups identified with the multivariable model, malignancy rate was assessed by using exact 95% confidence intervals.
Results
The median age of the patient population was 52 years (range, 30-81 years). Median lesion diameter (maximum span of calcifications) was 0.8 cm (range, 0.1-9.0 cm). At concurrent digital breast tomosynthesis in 20 women, amorphous calcifications were apparent on 14 of 20 (70%) images.
Malignancy was ultimately found in 52 of 497 (10.5%; 95% CI: 7.9, 13.5) lesions classified as amorphous calcifications (Table 1) . Of 52 malignancies, 17 (32.7%) were invasive, with median invasive size of 0.3 cm (range, 0.1-1.3 cm) at pathology. Six of 17 (35.3%) invasive cancers were grade 1 (all were invasive ductal carcinoma [IDC], two also had DCIS), and 11 (67%) were grade 2 (five IDC, five IDC with DCIS, one invasive lobular carcinoma). All invasive malignancies were node negative, estrogen and progesterone receptor positive, and human epidermal growth factor 2 negative, with 13 luminal A and four luminal B subtypes (inferred from receptor status, the latter with moderate or high Ki-67 proliferation index). The other 35 malignancies were DCIS: one (2.9%) was nuclear grade 1, 27 (77.1%) were nuclear grade 2, and seven (20%) were nuclear grade 3.
Among the 493 lesions with standard types of distribution (ie, excluding the four unusual lesions detailed in the Table 1 footnote), malignancy rates differed across different distribution categories (P , .001), with one of the lowest malignancy rates in the most prevalent "grouped" category at 25 of 356 (7.0%; 95% CI: 4.6, 10.2) ( Table 1, Fig 1) and the highest malignancy rates in the segmental category at six of 21 (28.6%; 95% CI: 11.3, 52.2) (Fig 2) , in the linear category at eight of 32 (25%; 95% CI: 11.5, 43.4) ( Fig 3) , and in multiple group distribution at nine of 36 (25%, 95% CI: 12.1, 42.2) (Fig 4) . Grouped distribution had a malignancy Table 2 summarizes relative rates of malignancy for distributions as compared with grouped lesions while adjusting for each of several factors known to be associated with malignancy (ie, age, family history, prior atypical biopsy, personal history of breast or ovarian cancer, breast density, associated mass or asymmetry, stability, and lesion size). The results shown in Table 2 demonstrate that after adjusting for any of the considered factors, malignancy rate in grouped lesions remained three to four times smaller than that in lesions with linear, segmental, or multiple group distributions. rate approximately four times lower (P , .01) than for any other distribution except "regional" (Fig 5) , which had a rate of two of 48 (4.2%, 95% CI: 0.5, 14.3).
Thirteen of the patients with amorphous calcifications distributed in multiple groups in the same quadrant underwent biopsy of a second group of calcifications that were considered part of the same lesion. Eight of these women had atypical results at the initial biopsy; five (63%) also had atypical results at the second biopsy, and three had fibrocystic change or sclerosing adenosis at the second biopsy. The remaining five women had benign results at both biopsies. After adjusting simultaneously for multiple factors in the logistic regression model, only distribution (P , .001), personal history of breast or ovarian cancer (P = .019), and interaction of age with distribution (P = .006) remained significant, with family history trending toward significance (P = .064). Age was also the only associated predictor of malignancy in grouped lesions, with malignancy rate increasing with increasing age (P = .006). Interestingly, in all other distributions, malignancy tended to be more frequent in younger women; however, this difference was not significant (P = .13). In particular, both malignancies with regional distribution occurred in women younger than 50 years, enabling us to clinically distinguish regional from grouped lesions despite the very similar malignancy rate across other considered factors.
Previous imaging findings were unavailable in 116 patients who underwent baseline imaging or who underwent prior imaging at an outside institution. Regardless of distribution, new or increasing amorphous calcifications were no more likely to be malignant, with an overall malignancy rate of 38 of 323 cases (11.8%), than were those that were deemed stable for at least 1 year (six of 57 [10.5%], P . .99). Malignancy rate was not influenced by associated asymmetry or mass. Of 17 invasive cancers, associated asymmetry was seen in three (17.6%) and a mass with indistinct margins was seen in one (5.9%). There were four invasive cancers in breasts with extremely dense parenchyma that could have potentially masked an associated mass or asymmetry.
Malignancy rates for combination of personal history, age, and lesion distribution are summarized in Table 3 . Consistent with multivariable analysis, the category of grouped amorphous calcifications in women younger than 50 years without a personal history of breast or ovarian cancer had the lowest malignancy rate of 3.1% (four of 127; 95% CI: 0.9, 7.9), with higher malignancy rates for other nonregional distributions. Among the four patients with cancer in this low-risk group, two had a known family history of breast cancer, and one had an unknown family history.
Risk Lesions
Atypical/risk histopathology was found at core biopsy of 144 (29.0%) of 497 lesions (Table 4) , with seven of these 144 (4.9%) lesions upgraded to malignancy at excision. The upgrade rate was one of six (16%) for LCIS and five of 85 (5.9%) for ADH. Of six lesions associated with LCIS at core biopsy, amorphous calcifications were found within LCIS at histopathology in three (50.0%) lesions, including the one malignant lesion (1.3-cm grade 2 invasive lobular carcinoma). Amorphous calcifications were found within 77 of 85 (90.5%) ADH lesions, including five upgraded to malignancy (one with 0.1-cm grade 1 IDC, four with DCIS [nuclear grade 2, n = 3; nuclear grade 1, n = 1]). The one flat epithelial atypia (FEA) lesion that was upgraded to DCIS at excision had calcifications within the FEA.
Of 356 grouped amorphous calcifications, 102 (28.7%) yielded risk histopathology at percutaneous biopsy. Of these 102, three (2.9%) were upgraded to malignancy at excision: Two of 63 (3.2%) grouped amorphous calcifications showing ADH at stereotactic biopsy were upgraded to nuclear grade 2 DCIS. Both were in women who were younger than 50 years and who had a family history of breast cancer in first-degree relatives; one of these women also had a personal history of breast cancer. One of 22 (4.5%) calcifications showing FEA at core biopsy in a woman with a family history of breast cancer was upgraded to nuclear grade 3 DCIS. None of 16 (0%) grouped amorphous calcifications showing ALH at stereotactic biopsy were upgraded at excision. Of 356 grouped amorphous calcifications, 127 (35.7%) occurred in women younger than 50 years without a personal history of breast or ovarian cancer; atypical histopathology results were present in 39 of 127 calcifications (30.7%), with no upgrades at excision.
Discussion
Across four prior series (4-7), the malignancy rate of biopsied amorphous calcifications was 53 of 266 (19.9%).
Our study supports diagnostic work-up (and biopsy) of amorphous calcifications; however, we observed a lower malignancy rate of 52 of 497 (10.5%; 95% CI: 7.9, 13.5), which is just barely above the 10% threshold used for a BI-RADS category 4b assessment (2) . For the most common distribution, grouped amorphous calcifications, we observed a malignancy rate of 25 of 356 (7.0%; 95% CI: 4.6, 10.2), which is in the range for a BI-RADS category 4a assessment. We used factors justified by multivariable analysis to identify as low risk the group of women younger than 50 years with no personal history of breast or ovarian cancer who had a malignancy rate of four of 127 (3.1%; 95% CI: 0.9, 7.9) at biopsy of grouped amorphous calcifications. Family history of breast cancer trended toward significance as a risk factor. Distribution of microcalcifications is a particularly important predictor of risk of malignancy. Liberman et al (4) reported malignancy in 36% of clustered calcifications (now referred to as "grouped"), 68% of linearly distributed calcifications, and 74% of those that were segmental. In the study by Berg et al (5) , amorphous calcifications in segmental and linear distributions were associated with malignancy in 43% and 40% of biopsies, respectively; however, these rates were not significantly greater than the malignancy rate of 17 of 100 (17%) for grouped calcifications. Our study showed that the malignancy rates for segmental amorphous calcifications (ie, 29%) and linearly distributed amorphous calcifications (ie, 25%) were significantly higher than the malignancy rate for grouped calcifications (ie, 7%) (P , .05 for both).
In a recent study, Iwase et al (8) showed only six of 216 (2.8%) grouped amorphous calcifications were malignant and suggested that biopsy of such calcifications would increase the number of false-positive findings. We found a higher malignancy rate for grouped amorphous calcifications (25 of 356 [7.0%]), which is similar to the findings of a recent study by Kim et al (9) , who found seven of 92 grouped amorphous calcifications (7.6%) were malignant (9) . We continue to recommend aggressive diagnostic work-up (typically including biopsy) of such findings. We found that grouped amorphous calcifications yielding ADH at core biopsy were infrequently upgraded to malignancy: Only two of 63 (3.2%) such lesions were upgraded, and both were intermediate nuclear-grade DCIS (in women aged 44 and 49 years; family history of breast cancer in both, personal history of breast cancer in one). Given the relatively low malignant potential in this subset of amorphous calcifications, these findings suggest imaging surveillance may be reasonable in lieu of excision, particularly in the absence of other risk factors; however, further study is warranted.
There were several limitations to our study. We retrospectively analyzed women who underwent stereotactic biopsy for breast microcalcifications. As such, we cannot know how many amorphous calcifications were observed rather than biopsied; however, at our institution, it is routine practice to biopsy such calcifications. The lack of follow-up after biopsy for 83 lesions and follow-up of less than 2 years in another 45 potentially limits our study and could contribute to false-negative results; however, we found a malignancy rate of 16 of 411 (3.9%) among those with average follow-up of 4.7 years (range, 1.3-7.9 years), and no cancer was thought to have been due to inadequate initial sampling. Further, it is currently routine practice to recommend routine screening after benign concordant stereotactic biopsy results (15, 16) . While the number of samples obtained during biopsy ranged from four to 13, we always documented calcification retrieval and aim for six 9-g specimens in our current practice. We recommend women resume routine screening mammography after a benign concordant core biopsy result.
In conclusion, with a malignancy rate of 10.5%, biopsy of amorphous calcifications remains appropriate. Fifty-two of 497 (10.5%; 95% CI 7.9 to 13.5) lesions proved malignant, including 17 of 52 (32.7%) invasive cancers (median, 0.3 cm; range, 0.1-1.3 cm), all of which were estrogen and progesterone receptor positive and node negative. In current . ADH was prioritized over other diagnoses, followed by atypical papilloma, LCIS, FEA, ALH, atypical apocrine adenosis, radial scar, and benign papilloma. † Two LCIS lesions also showed ADH at core biopsy, with no malignancy at excision. ‡ No atypical lesions showed both FEA and ALH at core biopsy. § Five lesions of ALH showed LCIS at excision as did one atypical papilloma. || One radial scar with microscopic papilloma showed pleomorphic LCIS at excision.
We found a subgroup of women younger than 50 years with no personal history of breast or ovarian cancer who had a lower rate of malignancy (four of 127 [3.1%]) for grouped amorphous calcifications. In this same group of women, 39 (30.7%) yielded atypical results prompting excision, and four of these women later developed malignancy an average of 3.6 years after initial biopsy of amorphous calcifications. The high rate of cancer at follow-up (four of 39 [10.3%]) in this subgroup of women several years after initial biopsy of amorphous calcifications yielding high-risk histopathology emphasizes the importance of continued imaging surveillance.
Low-suspicion microcalcifications of similar morphology distributed in multiple groups in both breasts have been considered to favor a benign origin (10), similar to multiple bilateral circumscribed masses (11, 12) . Importantly, we found a higher malignancy rate for amorphous calcifications in multiple ipsilateral groups in the same quadrant (nine of 36 [25.0%]) than for solitary grouped distribution (25 of 356 [7.0%]) (P = .002), Two prior series suggest that biopsy of one such group of calcifications can be used to predict outcome in the second group (5, 13) . Raj et al (14) suggest that one biopsy of morphologically similar segmental microcalfications spanning more than 5 cm is adequate for diagnosis rather than performing tissue sampling of both anterior and posterior aspects of the process. Our data also support management of similar groups on the basis of biopsy results from the most suspicious group, as 13 of the patients with multiple groups of amorphous calcifications in the same quadrant underwent more than one biopsy, with 10 of 13 (76.9%) yielding the same results as the initial biopsy (five additional sites of atypia and five additional benign results; three with atypia at one site were benign at the second site). All nine malignancies manifest as multiple groups of amorphous calcifications in the same quadrant showed malignancy at all groups at excision. practice, amorphous calcifications require tissue biopsy but are infrequently associated with aggressive malignancies, especially when they have solitary grouped distribution. In particular, in women younger than 50 years without history of breast or ovarian cancer, grouped amorphous calcifications have an approximately 3% (four of 127) malignancy rate, perhaps making surveillance a reasonable alternative to biopsy in this subset of patients, though further study is needed.
